Photo from wikipedia
Key Points • The median OS of patients with MCL was 1.6 years; a diagnosis of MCL-AHN and an abnormal karyotype were each associated with inferior outcomes.• Midostaurin was the… Click to show full abstract
Key Points • The median OS of patients with MCL was 1.6 years; a diagnosis of MCL-AHN and an abnormal karyotype were each associated with inferior outcomes.• Midostaurin was the most commonly used agent in MCL and was associated with improved OS in a multivariate analysis.
Keywords:
features survival;
cell leukemia;
clinical molecular;
leukemia clinical;
molecular features;
mast cell
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!